Skip 
Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 map map 

Access to Care: 1-800-239-2901

Medical Disorders
Resources
Basic InformationLookupsLatest News
What Will It Take for People to Embrace a COVID Vaccine?Smog Tied to Raised Risk for Parkinson's, Alzheimer's DiseaseWhat Will Convince Americans to Get a COVID-19 Vaccine?CDC Recommends Face Masks in All Public Transportation SettingsNewborns of Moms With COVID-19 Face Little Infection Risk: StudyAs Virtual Doctor Visits Spike, Concerns About Equity, Missed Diagnoses GrowMental Health Issues Double the Odds of Dying With COVID-19, Study FindsDuring Stress of Pandemic, Know Suicide's Warning SignsMost Newborns of COVID-19-Infected Moms Fare WellAccuracy of COVID-19 Antibody Tests Varies Widely, Study FindsGuard Yourself Against the Health Dangers of Wildfire SmokeWildfire Smoke Poses Special Threat to People With AsthmaCOVID Conflicts Are Putting Big Strains on RelationshipsEven Exercise May Not Ease Pandemic-Linked StressWest Coast Wildfires, COVID a Double Whammy to Lung HealthMasks Make Talking Even Tougher for People Who StutterWith COVID Vaccine in Works, 1 in 5 Americans Doesn't Believe in ShotsAHA News: COVID-19's Economic Fallout Expands Food Insecurity, as Groups Scramble to HelpCOVID-19 and Hurricane Season Could Be Deadly MixSprains, Strains? New Guidelines Urge OTC Painkillers, Not OpioidsAHA News: As Hurricane Season and Pandemic Collide, Here's How to Stay SafeCOVID-19 Clinical Trials Lack Diversity, Researchers SayGet Dizzy When Standing Up? It Could Be Risk Factor for DementiaLevels of Anxiety, Addiction, Suicidal Thoughts Are Soaring in the PandemicCOVID-19 Causing More Stress in America Than Other Nations: SurveyPandemic Could Complicate Hurricane Season11 States Could Face ICU Doc Shortages as Coronavirus Cases SurgeYet Another Study Finds Vaccines Are SafeIn Rush to Publish, Most COVID-19 Research Isn't Reliable, Experts SayMany U.S. Homes Too Cramped to Stop COVID-19's SpreadWith Safety Steps, Moms Unlikely to Pass COVID-19 to Newborns: StudyFace Masks Making Things Tough for the DeafU.S. Air Quality Got Better During Pandemic: StudyWill CPR Save Your Life? Study Offers a Surprising AnswerLupus Drug Prevents Low Heartbeat in High-Risk Newborns: StudyMasks, Video Calls: Pandemic Is Hampering Communication for Those With Hearing ProblemsCOVID-19 Deaths Have Already Left 1.2 Million Americans GrievingWill COVID Pandemic's Environmental Benefit Last?Exposure to Iodine in the NICU May Affect Infant Thyroid FunctionZika May Have Damaged More Infants' Brains Than ExpectedCoronavirus Ups Anxiety, Depression in the LGBTQ CommunityWill the COVID-19 Pandemic Leave a Mental Health Crisis in Its Wake?AHA News: Sadness and Isolation of Pandemic Can Make Coping With Grief HarderWildfire Smoke Causes Rapid Damage to Your Health: StudyCOVID-19 Typically Mild for Babies: StudyOne-Time Treatment Eases Parkinson's -- in MiceDrug Might Relieve Low Back Pain in Whole New WayBlood Donors Will Get Results of Coronavirus Antibody Test, Red Cross SaysAre Hardened Arteries a Risk Factor for Poor Slumber?Can Talk Therapy Heal the Body, Too?
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

COVID-19 Clinical Trials Lack Diversity, Researchers Say

HealthDay News
by -- Steven Reinberg
Updated: Aug 17th 2020

new article illustration

MONDAY, Aug. 17, 2020 (HealthDay News) -- Although minorities are paying a disproportionate price in the rate of COVID-19 illnesses and deaths, they are underrepresented in clinical trials, a new study finds.

The researchers call upon the government, medical journals and funders of research to make sure trials include minorities so that the results can be extrapolated to the U.S. population.

In the Adaptive COVID-19 Treatment Trial involving more than 1,000 patients testing the efficacy of the antiviral remdesivir, only 20% of participants are Black and 23% are Hispanic or Native American.

In the clinical trial funded by the drug's maker, Gilead, with nearly 400 patients, only 11% are Black and less than 1% are Hispanic or Native American.

"The overwhelming majority of the patients in both of those large clinical trials were Caucasians," said researcher Daniel Chastain, a clinical assistant professor of pharmacy at the University of Georgia's Albany campus.

"Knowing that African Americans die at a higher rate than Caucasians, can I say that this medication will work in them as well? Yes, they enrolled a bunch of patients and yes they got these data out as fast as possible, but can we use this information to inform treatments in all patients?" he said in a university news release.

The remdesivir trials found that patients given the drug recovered from COVID-19 a little faster than those given a placebo. But minority patients often have more severe symptoms and complications from the disease, so it's not clear if they will respond as well to the drug.

"Why aren't we putting up infrastructure for clinical trial sites in areas that were heavily hit by COVID?" Chastain said. "If we would've included Albany, those clinical trials would've been more diversified and would've been much more representative of what the coronavirus pandemic looks like in our area and throughout the U.S."

The report was published Aug. 12 in the New England Journal of Medicine.

More information

For more on COVID-19, head to the U.S. Centers for Disease Control and Prevention.